Senseonics and Beta Bionics have signed an agreement to advance the development of the artificial intelligence (AI) based iLet Bionic Pancreas system.

Under the alliance, Beta Bionics will integrate Senseonics’ Eversense continuous glucose monitoring (CGM) system into the bionic pancreas.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Eversense is designed as an implantable, long-term CGM device for continuous measurement of interstitial fluid glucose levels. The system then wirelessly transmits the readings to a smartphone app.

The purpose of adopting this system into the iLet is to enable real-time Eversense data to serve as a CGM option to drive the fully autonomous bionic pancreas.

Senseonics president and CEO Tim Goodnow said: “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.

“The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.”

“We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Beta Bionics is developing the dual-chamber, infusion pump iLet system to duplicate a biological pancreas via automatic and autonomous adjustment of insulin and glucagon dosing in order to meet the individual requirements of diabetes patients.

Beta Bionics president and CEO Ed Damiano said: “Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes.

“We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”